MARLBOROUGH, Mass., February 20, 2025--(BUSINESS WIRE)--Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today announced that its Affirm ® Contrast Biopsy Software, which combines ...

Hologic, Inc. HOLX signed a definitive agreement to acquire Focal Therapeutics. The deal, valued $125 million, will widen the Breast Health product suite. Also, the buyout will strengthen the ...

She will share her experiences with the Affirm 2D/3D upright biopsy, lateral arm approach and Brevera Breast Biopsy system, which integrates tissue acquisition, real-time imaging and verification ...

References 1 Hologic Data on File. Affirm Contrast Biopsy Instructions for Use. MAN-07748 Rev 002.